Literature DB >> 24021463

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

Xiaozhang Zheng1, Kenneth W Bair, Paul Bauer, Timm Baumeister, Krista K Bowman, Alexandre J Buckmelter, Maureen Caligiuri, Karl H Clodfelter, Yezhen Feng, Bingsong Han, Yen-Ching Ho, Nikolai Kley, Hong Li, Xiaorong Liang, Bianca M Liederer, Jian Lin, Justin Ly, Thomas O'Brien, Jason Oeh, Angela Oh, Dominic J Reynolds, Deepak Sampath, Geeta Sharma, Nicholas Skelton, Chase C Smith, Jarrod Tremayne, Leslie Wang, Weiru Wang, Zhongguo Wang, Hongxing Wu, Jiansheng Wu, Yang Xiao, Guangxing Yang, Po-wai Yuen, Mark Zak, Peter S Dragovich.   

Abstract

Potent, 1H-pyrazolo[3,4-b]pyridine-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using structure-based design techniques. Many of these compounds exhibited nanomolar antiproliferation activities against human tumor lines in in vitro cell culture experiments, and a representative example (compound 26) demonstrated encouraging in vivo efficacy in a mouse xenograft tumor model derived from the A2780 cell line. This molecule also exhibited reduced rat retinal exposures relative to a previously studied imidazo-pyridine-containing NAMPT inhibitor. Somewhat surprisingly, compound 26 was only weakly active in vitro against mouse and monkey tumor cell lines even though it was a potent inhibitor of NAMPT enzymes derived from these species. The compound also exhibited only minimal effects on in vivo NAD levels in mice, and these changes were considerably less profound than those produced by an imidazo-pyridine-containing NAMPT inhibitor. The crystal structures of compound 26 and the corresponding PRPP-derived ribose adduct in complex with NAMPT were also obtained.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Nicotinamide phosphoribosyltransferase (NAMPT); Tumor metabolism; X-ray crystal structure

Mesh:

Substances:

Year:  2013        PMID: 24021463     DOI: 10.1016/j.bmcl.2013.08.074

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Authors:  Thomas O'Brien; Jason Oeh; Yang Xiao; Xiaorong Liang; Alexander Vanderbilt; Ann Qin; Lulu Yang; Leslie B Lee; Justin Ly; Ely Cosino; Jennifer A LaCap; Annie Ogasawara; Simon Williams; Michelle Nannini; Bianca M Liederer; Peter Jackson; Peter S Dragovich; Deepak Sampath
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

2.  The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.

Authors:  J Patrick Murphy; Michael A Giacomantonio; Joao A Paulo; Robert A Everley; Barry E Kennedy; Gopal P Pathak; Derek R Clements; Youra Kim; Cathleen Dai; Tanveer Sharif; Steven P Gygi; Shashi Gujar
Journal:  Cell Rep       Date:  2018-08-28       Impact factor: 9.423

3.  Crystal structure-based comparison of two NAMPT inhibitors.

Authors:  Sai-Long Zhang; Tian-Ying Xu; Zhen-Lin Yang; Shuo Han; Qiang Zhao; Chao-Yu Miao
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

4.  EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.

Authors:  Sameer H Issaq; Arnulfo Mendoza; Ria Kidner; Tracy I Rosales; Damien Y Duveau; Christine M Heske; Jason M Rohde; Matthew B Boxer; Craig J Thomas; Ralph J DeBerardinis; Lee J Helman
Journal:  Mol Cancer Ther       Date:  2020-05-05       Impact factor: 6.261

Review 5.  New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.

Authors:  Anne Roulston; Gordon C Shore
Journal:  Mol Cell Oncol       Date:  2015-06-10

6.  Metoprolol Protects Against Arginine Vasopressin-Induced Cellular Senescence in H9C2 Cardiomyocytes by Regulating the Sirt1/p53/p21 Axis.

Authors:  Qiang Li; Kang Huang; Tianyi Ma; Shijuan Lu; Shilin Tang; Miao Wu; Hui Yang; Jianghua Zhong
Journal:  Cardiovasc Toxicol       Date:  2021-11-20       Impact factor: 3.231

Review 7.  1H-Pyrazolo[3,4-b]pyridines: Synthesis and Biomedical Applications.

Authors:  Ana Donaire-Arias; Ana Maria Montagut; Raimon Puig de la Bellacasa; Roger Estrada-Tejedor; Jordi Teixidó; José I Borrell
Journal:  Molecules       Date:  2022-03-30       Impact factor: 4.411

Review 8.  Advances in NAD-Lowering Agents for Cancer Treatment.

Authors:  Moustafa S Ghanem; Fiammetta Monacelli; Alessio Nencioni
Journal:  Nutrients       Date:  2021-05-14       Impact factor: 5.717

9.  Structural basis for resistance to diverse classes of NAMPT inhibitors.

Authors:  Weiru Wang; Kristi Elkins; Angela Oh; Yen-Ching Ho; Jiansheng Wu; Hong Li; Yang Xiao; Mandy Kwong; Mary Coons; Bobby Brillantes; Eric Cheng; Lisa Crocker; Peter S Dragovich; Deepak Sampath; Xiaozhang Zheng; Kenneth W Bair; Thomas O'Brien; Lisa D Belmont
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

10.  Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.

Authors:  Sei-Ichi Tanuma; Kiyotaka Katsuragi; Takahiro Oyama; Atsushi Yoshimori; Yuri Shibasaki; Yasunobu Asawa; Hiroaki Yamazaki; Kosho Makino; Miwa Okazawa; Yoko Ogino; Yoshimi Sakamoto; Miyuki Nomura; Akira Sato; Hideaki Abe; Hiroyuki Nakamura; Hideyo Takahashi; Nobuhiro Tanuma; Fumiaki Uchiumi
Journal:  Molecules       Date:  2020-08-10       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.